Coaching may boost cancer pill adherence in new study
NCT ID NCT07521202
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether extra education and counseling helps women with HR+/HER2- early breast cancer take their prescribed medication, abemaciclib, more consistently. About 257 women will either receive standard care or additional coaching. The main goal is to see if coaching reduces the number of women who stop taking the drug early.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+/HER2- EARLY BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Obstetrics and Gynaecology
Erlangen, Bavaria, 91054, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Coaching may boost adherence to breast cancer therapy
- Breast cancer trial lets early response guide treatment switch
- New breast cancer trial aims to skip chemo for some patients
- Could a pill replace chemo for some breast cancer patients?
- Breast cancer drug adherence under the microscope: will patients stick with treatment?
- New study could spare some breast cancer patients from chemo